NOVARTIS AG NAMENS-AKTIEN SF 0,5/ CH0012005267 /
03/08/2024 13:03:49 | Chg. 0.000 | Volume | Bid13:03:49 | Ask13:03:49 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
100.720EUR | 0.00% | - Turnover: - |
100.720Bid Size: - | 102.900Ask Size: - | 231.61 bill.EUR | - | - |
GlobeNewswire
26/06
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
13/06
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
16/04
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
14/03
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
28/02
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
10/01
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
05/01
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
02/01
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
19/12/2023
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire
11/12/2023
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire
08/12/2023
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire
06/12/2023
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
GlobeNewswire
20/11/2023
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH